drugset / Trial / NCT01487083

A Long-Term Study in Schizophrenia

NCT01487083

Phase 3 Terminated 282 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety of pomaglumetad methionil in participants with schizophrenia.

Timeline

Start
2011-12
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2140023 Unknown 20 mg Oral
Subject LY2140023 Unknown 40 mg Oral
Subject LY2140023 Unknown 80 mg Oral

Indications